Becton Dickinson (XSWX:BDX) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BDX Becton Dickinson & Co XSWX:BDX
73 GF Score
Price CHF127.84
GF Value CHF152.74
! 3 Warning Signs
View Full Analysis

What is Becton Dickinson Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

XSWX:BDX
73GF Score
Becton Dickinson & Co XSWX:BDX
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Becton Dickinson (XSWX:BDX) Overvalued in 2026?

Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued. The current stock price of CHF127.84 is trading 16.3% below its estimated GF Value™ of CHF152.74.

Key valuation signals for XSWX:BDX:

  • Total Noninterest Expense:
  • GF Value™: CHF152.74 vs. price of CHF127.84 (16.3% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the XSWX:BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Becton Dickinson Business Description

Address 1 Becton Drive, Franklin Lakes, NJ, USA, 07417-1880
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
73GF Score

Get the complete analysis for XSWX:BDX

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF127.84
Price
CHF152.74
GF Value